Echoiq Limited

The Business

EIQ develops AI software that analyses echocardiograms to detect cardiac conditions. Its core product screens for aortic stenosis, a narrowing of a heart valve that kills roughly half of symptomatic patients within two years if untreated. The software holds FDA clearance for aortic stenosis detection, and a second indication covering heart failure screening is currently under FDA review. Revenue comes almost entirely from a handful of Australian hospital sites. The US market, where the commercial opportunity is concentrated, has generated no customer receipts despite three closed-won accounts from a pipeline of 50 or more.

Recent Performance

Revenue rose from A$45,000 in FY24 to A$101,000 in FY25, off a near-zero base. These figures are rounding errors against annual operating losses of approximately A$15 million. The company applied twice for dedicated CPT reimbursement codes, the billing categories US hospitals use to recover costs from insurers, and was rejected in both September and October 2025. Performance rights requiring A$2 million in revenue by December 2025 lapsed unmet. The share price has roughly doubled over the past year, driven by AI-sector sentiment rather than any measurable commercial progress.

Outlook

Two binary events define the next 12 months. The first is the FDA decision on heart failure screening, expected in H2 CY2026, which would add a second cleared indication and strengthen the clinical proposition for US hospital adoption. The second is the CMAA reimbursement framework, a new Medicare pathway for AI-assisted diagnostics, which could create the billing mechanism hospitals need to justify deploying EIQ's software. Without reimbursement, hospitals carry no economic incentive to adopt, regardless of clinical performance. The company burns approximately A$12-13 million per year and held A$11.9 million in cash at last report, providing roughly 4.5 quarters of runway. A capital raise is required within 12 months under every scenario, and the terms of that raise will be consequential for existing holders.

Key Risks

Reimbursement failure is the primary risk. If the CMAA framework does not materialise, or produces rates insufficient to cover hospital workflow costs, the standalone commercial model has no viable path to revenue at scale. Two CPT code rejections already demonstrate that FDA clearance does not automatically translate to a billing mechanism. The structural lag between regulatory approval and reimbursement infrastructure in US healthcare is measured in years, not months, and this affects the entire standalone AI diagnostics sector, not EIQ specifically.

A dilutive capital raise is a near-certainty within 12 months given the cash position and burn rate. If the raise occurs at materially lower prices than today, the share count expansion would substantially dilute existing holders. The pricing of that raise will function as a market verdict on the company's commercial prospects at the time.

OEM free bundling represents a structural competitive threat. GE Healthcare acquired Caption Health in 2023 and now bundles cardiac AI guidance for free at hundreds of hospital sites. EIQ's clinical sensitivity data is superior, but the company must demonstrate that hospitals will pay a premium for incremental accuracy when a free alternative already exists. No evidence of that willingness has emerged.

What to Watch

The CMAA reimbursement framework decision, expected in H2 CY2026, is the thesis-defining event. It determines whether US hospitals have any economic mechanism to pay for AI-assisted echocardiography. Without it, the commercial model cannot function regardless of clinical performance or FDA clearance status.

• H2 CY2026 FDA Heart Failure 510(k) Decision — clearance would add a second indication and expand the addressable clinical use case, but commercial impact depends on reimbursement progressing in parallel.
• Next 12 months Capital Raise Announcement — a raise is required under every scenario modelled; the pricing and dilution terms will signal how the market and institutional investors assess the company's near-term prospects.
• Next 12 months First US Customer Cash Receipt — any dollar amount received from a US customer would validate willingness-to-pay and is the single most important observable signal for the business model's viability.

Company Description

EIQ operates a single business: AI-powered analysis of echocardiograms to screen for cardiac disease. The software sits on top of existing ultrasound hardware, processing echo images through proprietary algorithms trained on a database of over 1.3 million echocardiograms held under a 12.5-year exclusivity agreement with Australia's National Echo Database (NEDA). The company currently holds one FDA-cleared product for aortic stenosis detection and has a second indication, heart failure screening, under FDA review. A third module covering cardiac amyloidosis, a rare protein-deposit disease, is in earlier development. Revenue is negligible at approximately A$180,000 annualised, sourced almost entirely from a handful of Australian hospital deployments. The Mayo Clinic has signed a distribution agreement for the heart failure product, conditional on FDA clearance.

Where the Growth Is

The entire growth thesis rests on US hospital adoption of AI-assisted echocardiography, which itself depends on the CMAA reimbursement framework being implemented. This segment currently contributes zero revenue. Usage metrics show early operational traction: 9,220 echoes were processed in the most recent quarter, up 131% quarter-on-quarter from a base of approximately 4,000. The pipeline lists 50 or more hospital accounts, though only three have converted to closed-won status, a conversion rate of approximately 6% with undisclosed commercial terms. The gap between pipeline volume and contracted revenue is the key commercial variable to track.

Competitive Position

EIQ's competitive advantages are real but carry a defined shelf life. The 99.5% sensitivity figure, published in JACC, exceeds what OEM-embedded AI tools currently achieve. FDA clearance for aortic stenosis creates a regulatory barrier of roughly 12-18 months for any competitor seeking to replicate that specific indication. The NEDA database, with its 12.5-year exclusivity, provides a training data advantage that would be costly and slow to replicate.

The structural vulnerability sits with GE Healthcare, which acquired Caption Health in 2023 for approximately US$400 million and now bundles cardiac AI guidance for free at hundreds of hospital sites. When the largest ultrasound manufacturer offers a competing product at zero cost, standalone pricing power is deeply compromised for any independent vendor. EIQ's clinical superiority is documented, but the company must demonstrate that hospitals will pay a premium for better sensitivity when a free alternative exists. The competitive window before OEM algorithms close the sensitivity gap is approximately three to five years. No evidence of market willingness-to-pay has yet emerged, which makes this the most important unresolved question for the investment case.

Management and Capital Discipline

The clinical team has executed consistently, delivering FDA clearance, the JACC publication, and the Mayo Clinic partnership. The commercial team has not. Management has achieved none of its stated revenue or FDA timing targets. The Class F performance rights, which required A$2 million in revenue by December 2025, lapsed unmet. Forward guidance has consisted of repeated assertions that FDA heart failure clearance is expected "in coming months," a phrase that has appeared across multiple consecutive disclosures without resolution.

Stock-based compensation runs at approximately A$5 million per year against A$180,000 in revenue, producing over 3% annual dilution for existing holders. Capital allocation is conservative in structure (zero debt, A$11.9 million cash) but the burn rate of A$12-15 million annually means the cash position has an expiry date measured in quarters. The distinction between clinical execution and commercial execution matters here: the former has been strong, the latter has not been tested under conditions that required it to perform.

Financial Position

The balance sheet carries zero debt and A$11.9 million in cash. At the current burn rate of approximately A$3.5 million per quarter, this provides roughly 4.5 quarters of runway. An R&D tax rebate of approximately A$0.8 million annually provides marginal relief. The NEDA intangible asset sits on the books at A$4.4 million, though its commercial value remains unproven and its liquidation value to a third party is uncertain.

A capital raise is required within 12 months under every scenario modelled. If the raise occurs at the current share price, existing holders face approximately 25% dilution from share issuance. If the share price deteriorates materially before the raise, dilution could reach 60-80%, expanding the share count from 650 million toward 1.1-1.8 billion. The terms of the raise, when announced, will carry significant information content about institutional appetite for the company's prospects at that point in time.